PrEP (pre-exposure prophylaxis) works very effectively at preventing HIV transmission, whether taken daily or "on demand." In 2012, the FDA (U.S. Food and Drug Administration) approved tenofovir/emtricitabine (Truvada) for use as PrEP based on two large efficacy studies -- the iPrEX trial and the Partners PrEP trial. Then, in 2015, the IPERGAY study found that taking PrEP "on demand," meaning before and after sex, reduced HIV transmission risk by an average of 86%.
Despite these overwhelming results showing that PrEP works, uptake has been slow in the U.S. and around the world. We asked providers and community leaders what they thought needed to happen for PrEP to reach everybody who needs it.
Interviews for this slide show were conducted by Terri Wilder, M.S.W., and Warren Tong.